Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. That said, here are three cash-producing companies that don’t make the cut and some better opportunities instead.
Etsy (ETSY)
Trailing 12-Month Free Cash Flow Margin: 21.6%
Founded by a struggling amateur furniture maker Robert Kalin and his two friends, Etsy (NYSE:ETSY) is one of the world’s largest online marketplaces, focusing on handmade or vintage items.
Why Is ETSY Not Exciting?
- Intense competition is diverting traffic from its platform as its active buyers fell by 2.1% annually
- Demand will likely be soft over the next 12 months as Wall Street’s estimates imply tepid growth of 1.3%
- Earnings growth underperformed the sector average over the last three years as its EPS grew by just 1.4% annually
Etsy’s stock price of $84.50 implies a valuation ratio of 14.3x forward EV/EBITDA. If you’re considering ETSY for your portfolio, see our FREE research report to learn more.
Ingersoll Rand (IR)
Trailing 12-Month Free Cash Flow Margin: 15.4%
Started with the invention of the steam drill, Ingersoll Rand (NYSE:IR) provides mission-critical air, gas, liquid, and solid flow creation solutions.
Why Does IR Worry Us?
- Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
- Earnings growth underperformed the sector average over the last two years as its EPS grew by just 3.2% annually
- ROIC of 6.3% reflects management’s challenges in identifying attractive investment opportunities
At $78.67 per share, Ingersoll Rand trades at 21.8x forward P/E. To fully understand why you should be careful with IR, check out our full research report (it’s free).
United Therapeutics (UTHR)
Trailing 12-Month Free Cash Flow Margin: 34.6%
Founded by a mother seeking treatment for her daughter's pulmonary arterial hypertension, United Therapeutics (NASDAQ:UTHR) develops and commercializes medications for chronic lung diseases and other life-threatening conditions, with a focus on pulmonary hypertension treatments.
Why Are We Hesitant About UTHR?
- Projected sales decline of 15.5% for the next 12 months points to a tough demand environment ahead
- Efficiency has decreased over the last five years as its adjusted operating margin fell by 6.6 percentage points
- Free cash flow margin shrank by 1.8 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
United Therapeutics is trading at $518.66 per share, or 17.8x forward P/E. Check out our free in-depth research report to learn more about why UTHR doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.